Gene Variant Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Gene MDM2
Variant amp
Impact List none
Protein Effect no effect
Gene Variant Descriptions MDM2 amp indicates an increased number of copies of the MDM2 gene. However, the mechanism causing the increase is unspecified.
Associated Drug Resistance
Category Variants Paths

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

No Variant Reference Transcript is Available.
No transcript is Available.

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
MDM2 amp neuroendocrine tumor predicted - sensitive Milademetan Case Reports/Case Series Actionable In a Phase I trial, Milademetan demonstrated safety and preliminary activity in patients with advanced solid tumors, and resulted in prolonged stable disease in 2 patients with MDM2-amplified tumors, 1 with liposarcoma and 1 with carcinoid tumor (J Clin Oncol 34, 2016 (suppl; abstr 2581; NCT01877382). detail...
MDM2 amp urinary bladder cancer no benefit Atezolizumab Case Reports/Case Series Actionable In a clinical case study, a patient with metastatic bladder cancer that harbored MDM2 amplification and other mutations quickly progressed after receiving Tecentriq (atezolizumab), resulting in new liver metastasis and a 258% increase of existing liver metastasis size 1.9 months after treatment (PMID: 28351930). 28351930
MDM2 amp triple-receptor negative breast cancer no benefit Pembrolizumab Case Reports/Case Series Actionable In a clinical case study, a patient with triple-receptor negative breast cancer that harbored MDM2 amplification quickly progressed after receiving Keytruda (pembrolizumab), resulted in new chest wall metastasis and a 55% increase of existing lung metastasis size 1.5 months after treatment (PMID: 28351930). 28351930
MDM2 amp endometrial stromal sarcoma no benefit Nivolumab Case Reports/Case Series Actionable In a clinical case study, a patient with endometrial stromal sarcoma that harbored MDM2 amplification quickly progressed after receiving Opdivo (nivolumab), resulted in new abdominal metastasis and a 242% increase of existing liver metastasis size within 1.5 months of treatment (PMID: 28351930). 28351930
MDM2 amp Advanced Solid Tumor no benefit N/A Clinical Study Emerging In a clinical study, 100% (5/5) of solid tumor patients harboring MDM2 amplification experienced disease progression within 2 months of anti-PD1/PD-L1 monotherapy, indicating a risk for hyperprogression on immunotherapy (PMID: 28351930). 28351930
MDM2 amp liposarcoma predicted - sensitive GDC-0575 + Gemcitabine Preclinical - Cell line xenograft Actionable In a preclinical study, GDC-0575 and Gemzar (gemcitabine) synergistically induced apoptosis and cell cycle arrest in liposarcoma cells harboring MDM2 amplification in culture, and inhibited tumor growth, prolonged progression-free survival in cell line xenogrft models (PMID: 29409053). 29409053
MDM2 amp liposarcoma predicted - sensitive unspecified MDM2 inhibitor Phase I Actionable In a Phase I trial, treatment with an unspecified MDM2 inhibitor resulted in clinical efficacy in six patients with liposarcoma harboring MDM2 amplification, including three patients with a partial response and two patients with stable disease for 15.7 months and 4.7 months (PMID: 30237864). 30237864
MDM2 amp dedifferentiated liposarcoma predicted - sensitive BI 907828 Preclinical - Pdx Actionable In a preclinical study, BI 907828 treatment resulted in tumor regression in patient-derived xenograft (PDX) models of dedifferentiated liposarcoma harboring MDM2 amplification (PMID: 31201607). 31201607
MDM2 amp liposarcoma predicted - sensitive BI 907828 Case Reports/Case Series Actionable In a Phase I trial, BI 907828 treatment led to a partial response in 3 of 7 patients with liposarcoma, all responders harbored MDM2 amplification (Ann Oncol 32 (2021): S1294; NCT03449381). detail...
MDM2 amp dedifferentiated liposarcoma sensitive Milademetan Phase I Actionable In a Phase I trial, Milademetan treatment resulted in an objective response rate of 3.8% (2/53, 2 partial responses), a disease control rate of 58.5%, and a median progression-free survival of 7.2 months in patients with dedifferentiated liposarcoma, 100% (22/22) of the patients tested for MDM2 had MDM2 amplification (CN > 6) with a median CN of 28.6 (PMID: 36669146; NCT01877382). 36669146
MDM2 amp well-differentiated liposarcoma not applicable N/A Clinical Study Diagnostic MDM2 amplification aids in the diagnosis of well-differentiated liposarcoma (PMID: 33799733, PMID: 34984861, PMID: 35074968, PMID: 36674856). 36674856 33799733 34984861 35074968
MDM2 amp dedifferentiated liposarcoma not applicable N/A Clinical Study Diagnostic MDM2 amplification aids in the diagnosis of dedifferentiated liposarcoma (PMID: 36674856, PMID: 35074968, PMID: 18500263, PMID: 33799733). 33799733 36674856 35074968 18500263
MDM2 amp parosteal osteosarcoma not applicable N/A Clinical Study Diagnostic MDM2 amplification aids in the diagnosis of parosteal osteosarcoma (PMID: 33799733, PMID: 24786129, PMID: 21336260, PMID: 20601938). 20601938 33799733 24786129 21336260
MDM2 amp osteosarcoma sensitive BI 907828 Preclinical - Cell line xenograft Actionable In a preclinical study, BI 907828 induced tumor regression in a cell line xenograft model of MDM2-amplified osteosarcoma (PMID: 39259562). 39259562